As 2026 begins, pharma leaders are placing sharper bets earlier while navigating increasing pressure across pricing, access, and evidence. In this episode, Matt Riordan, Group President, Putnam, shares a candid, executive-level view of what leaders are prioritizing this year, where confidence is high, and where blind spots may limit impact. Drawing on real-world leadership conversations, the discussion explores how access and evidence expectations are shifting upstream and what it takes to pressure-test assumptions, align strategy earlier, and lead with greater clarity in 2026.

Panel – Mindy McGrath, Matt Riordan  

Recording & Editing – Mike Liberto, Rachel Skonecki 

For additional discussion, please contact us at TrendingHealth.com.